Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer,
has limited value for treatment decisions due to questionable analytical validity. The …

Oestrogen receptor-positive (ER + ) breast cancer is a major cause of cancer death in
women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …

Full article: Physiological, vestibulo-ocular and cervicogenic post-concussion disorders: An
evidence-based classification system with directions for treatment Skip to Main Content …

Background We tested the hypothesis that the level of circulating tumor cells can predict
survival in metastatic breast cancer. Methods In a prospective, multicenter study, we tested 177 …

Purpose To improve on current standards for breast cancer prognosis and prediction of
chemotherapy benefit by developing a risk model that incorporates the gene expression–based “…

… Dr MJ Ellis is a founder of University Genomics, Inc. and owns stock in this company. Dr
TO Nielsen is a codirector of the tissue microarray unit of the Genetic Pathology Evaluation …

Background The recurrence score based on the 21-gene breast cancer assay predicts
chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it …

Background Validation of a novel gene expression signature in independent data sets is a
critical step in the development of a clinically useful test for cancer patient risk-stratification. …

Somatic mutations have been extensively characterized in breast cancer, but the effects of
these genetic alterations on the proteomic landscape remain poorly understood. Here we …

Background Prior studies with the use of a prospective–retrospective design including
archival tumor samples have shown that gene-expression assays provide clinically useful …